X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ALM-488 is a proprietary fluorescent peptide-dye conjugate in the visible spectrum and can be visualized with fluorescently enabled instrumentation including filter modified loupe systems, portable handheld systems, microscopes and laparoscopes.
Lead Product(s): ALM-488
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ALM-488
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
ALM-488 is a fluorescently labelled nerve targeting drug, which acts as an adjunct for the visualization of nerves at risk for injury during head and neck surgery. The Fast Track designation is based on a Phase 1/2 trial in patients undergoing head and neck surgery.
Lead Product(s): ALM-488
Therapeutic Area: Oncology Product Name: ALM-488
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
Alume is conducting a Phase 1/2 clinical trial of ALM-488 in patients undergoing Head and Neck surgery. The Phase II SBIR grant is a follow-on 2–year award that will support testing of Alume's fluorescent nerve targeting agent in an ongoing Phase 1/2 clinical trial.
Lead Product(s): ALM-488
Therapeutic Area: Oncology Product Name: ALM-488
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
